Skip to Content
Event ANT Neuromeeting 2027 - Berlin starts on Jan 14, 2027, 8:00:00 AM (Europe/Berlin)
The utility of cognitive ERPs in the management of addictive disorders.
1/14/27, 11:00 AM - 1/14/27, 11:30 AM (Europe/Berlin) (30 minutes)
The utility of cognitive ERPs in the management of addictive disorders.
Dr. Salvatore Campanella
Research Director of Laboratory of Medical Psychology and Addictions at Université Libre de Bruxelles
Dr. Salvatore Campanella
Research Director of Laboratory of Medical Psychology and Addictions at Université Libre de Bruxelles
Biography:
Salvatore Campanella has a background of neuropsychologist, and he obtained his PhD at the University of Louvain-la-Neuve, Belgium in 2001. He got a full-time researcher position from the Belgian National Fund of Scientific Research (FNRS) in 2008. He is currently “Research Director” of the Laboratory of Medical Psychology and Addictions, situated at the heart of the Brugmann Hospital, at the University of Brussels (ULB), Belgium. His main work is devoted to the finding of predictive EEG biomarkers to help in the management of psychiatric disorders, with a specific focus on addictive disorders. He is currently the Specialty Chief Editor for Addictive Behaviors in Frontiers in Psychology. He is also the secretary and president-elect of the EEG and Clinical Neuroscience Society (ECNS).

Talk Abstract
A main concern for clinicians facing with addictive disorders is the relapse rate, around 50% at three-months following detoxification programs. In this presentation, I will present some cognitive event-related potentials (ERP) data suggesting how longitudinal ERP test-retest sessions may be useful in the clinical management of addictive disorders. By using tasks focusing on cue reactivity and inhibitory neurocognitive processes, we identified protective biomarkers supporting abstinence. Indeed, recovering inhibitory resources (increased No-go P3 component) and decreasing cue reactivity towards addiction-related (decreased oddball P3 component) cues are protective factors against early relapse. Besides grand)-averaged data, such results have been also assessed at the individual level. Of course, these are not sufficient, but necessary, factors supporting abstinence, and such ERP data should be included in a more global clinical assessment monitoring the evolution of important social/clinical parameters. Greater sample size is still needed, and multi-centers collaborative studies will be promoted.